Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 20/20 | 0.45 |
| ▸ | NR1I2 | O75469 | 7/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 7/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 7/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22347445 | 0.79 | NR1H4 (0.42) | NR1H4NR1I2CYP2C9CYP2C19 | |
| SCHEMBL22347833 | 0.77 | NR1H4 (0.41) | NR1H4NR1I2CYP2C9CYP2C19 | |
| SCHEMBL22347756 | 0.76 | NR1H4 (0.40) | NR1H4NR1I2CYP2C9CYP2C19 | |
| SCHEMBL22347354 | 0.75 | NR1H4 (0.53) | NR1H4NR1I2CYP2C9CYP2C19 | |
| SCHEMBL22347355 | 0.75 | NR1H4 (0.46) | NR1H4NR1I2CYP2C9CYP2C19 | |
| SCHEMBL24259641 | 0.74 | NR1H4 (0.39) | NR1H4NR1I2CYP2C9CYP2C19 | |
| SCHEMBL22347616 | 0.72 | NR1H4 (0.46) | NR1H4NR1I2CYP2C9CYP2C19 | |
| SCHEMBL29532117 | 0.72 | NR1H4 (0.46) | NR1H4NR1I2CYP2C9CYP2C19 | |
| SCHEMBL22347961 | 0.70 | — | — | |
| SCHEMBL22347276 | 0.68 | NR1H4 (0.40) | NR1H4NR1I2CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3924336-A1 | SUBSTITUTED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | Bristol-Myers Squibb Company (US) | 2021-12-22 | — | — | EP | disclosed |
| WO-2020168143-A1 | SUBSTITUTED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-08-20 | — | — | WO | disclosed |